Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Collegium Pharmaceutical (COLL) over the last 6 years, with Q3 2025 value amounting to $667000.0.

  • Collegium Pharmaceutical's Current Deferred Revenue fell 9966.29% to $667000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $667000.0, marking a year-over-year decrease of 9966.29%. This contributed to the annual value of $191.5 million for FY2024, which is 2782.03% up from last year.
  • Latest data reveals that Collegium Pharmaceutical reported Current Deferred Revenue of $667000.0 as of Q3 2025, which was down 9966.29% from $172.4 million recorded in Q2 2025.
  • Collegium Pharmaceutical's 5-year Current Deferred Revenue high stood at $197.8 million for Q3 2024, and its period low was $667000.0 during Q3 2025.
  • In the last 4 years, Collegium Pharmaceutical's Current Deferred Revenue had a median value of $162.2 million in 2022 and averaged $151.8 million.
  • Data for Collegium Pharmaceutical's Current Deferred Revenue shows a peak YoY increase of 3621.41% (in 2025) and a maximum YoY decrease of 9966.29% (in 2025) over the last 5 years.
  • Quarter analysis of 4 years shows Collegium Pharmaceutical's Current Deferred Revenue stood at $156.9 million in 2022, then decreased by 4.53% to $149.8 million in 2023, then increased by 27.82% to $191.5 million in 2024, then tumbled by 99.65% to $667000.0 in 2025.
  • Its Current Deferred Revenue was $667000.0 in Q3 2025, compared to $172.4 million in Q2 2025 and $188.3 million in Q1 2025.